OA10499A - Guanine derivative - Google Patents

Guanine derivative Download PDF

Info

Publication number
OA10499A
OA10499A OA70051A OA70051A OA10499A OA 10499 A OA10499 A OA 10499A OA 70051 A OA70051 A OA 70051A OA 70051 A OA70051 A OA 70051A OA 10499 A OA10499 A OA 10499A
Authority
OA
OAPI
Prior art keywords
hydrochloride
valaciclovir
crystalline
valaciclovir hydrochloride
crystalline form
Prior art date
Application number
OA70051A
Other languages
English (en)
Inventor
Barry Howard Carter
Peter Gregory Varlashkin
Richard Augustus Winnike
Grubb William Bayne Iii
Gregory Alan Conway
Philip George Lake
David Michael Skinner
David James Whatrup
Jane Muse Partin
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA10499(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of OA10499A publication Critical patent/OA10499A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
OA70051A 1995-01-20 1997-07-16 Guanine derivative OA10499A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9501178.9A GB9501178D0 (en) 1995-01-20 1995-01-20 Guanine derivative

Publications (1)

Publication Number Publication Date
OA10499A true OA10499A (en) 2002-04-10

Family

ID=10768347

Family Applications (1)

Application Number Title Priority Date Filing Date
OA70051A OA10499A (en) 1995-01-20 1997-07-16 Guanine derivative

Country Status (40)

Country Link
US (1) US6107302A (index.php)
EP (1) EP0804436B1 (index.php)
JP (1) JP3176633B2 (index.php)
KR (1) KR100376074B1 (index.php)
CN (1) CN1049893C (index.php)
AP (1) AP662A (index.php)
AR (1) AR002270A1 (index.php)
AT (1) ATE302777T1 (index.php)
AU (1) AU702794B2 (index.php)
BG (1) BG63393B1 (index.php)
BR (1) BR9606768A (index.php)
CA (1) CA2210799C (index.php)
CY (1) CY2531B1 (index.php)
CZ (1) CZ297065B6 (index.php)
DE (1) DE69635106T2 (index.php)
DK (1) DK0804436T3 (index.php)
EA (1) EA000364B1 (index.php)
EE (1) EE03528B1 (index.php)
ES (1) ES2248806T3 (index.php)
FI (1) FI973063A7 (index.php)
GB (1) GB9501178D0 (index.php)
GE (1) GEP20001940B (index.php)
HR (1) HRP960024B1 (index.php)
HU (1) HU222993B1 (index.php)
IL (1) IL116831A (index.php)
IN (1) IN182468B (index.php)
IS (1) IS2268B (index.php)
NO (1) NO315558B1 (index.php)
NZ (1) NZ298851A (index.php)
OA (1) OA10499A (index.php)
PL (1) PL182175B1 (index.php)
RO (1) RO118693B1 (index.php)
RS (1) RS49518B (index.php)
SI (1) SI0804436T1 (index.php)
SK (1) SK285329B6 (index.php)
TR (1) TR199700656T1 (index.php)
UA (1) UA46001C2 (index.php)
UY (1) UY25779A1 (index.php)
WO (1) WO1996022291A1 (index.php)
ZA (1) ZA96449B (index.php)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
CA2243237C (en) * 1996-01-19 2008-09-02 Glaxo Group Limited Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application
IT1283447B1 (it) * 1996-07-18 1998-04-21 Ind Chimica Srl Processo di preparazione del valaciclovir e relativi intermedi
WO1998031683A1 (en) * 1997-01-17 1998-07-23 Ajinomoto Co., Inc. Novel z-valacyclovir crystals
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
DE50209483D1 (de) * 2001-02-24 2007-03-29 Boehringer Ingelheim Pharma Xanthinderivate, deren herstellung und deren verwendung als arzneimittel
CA2457835A1 (en) * 2001-09-07 2003-03-20 Teva Pharmaceutical Industries Ltd. Crystalline forms of valacyclovir hydrochloride
AU2002348022B2 (en) * 2001-11-05 2006-06-15 Glaxo Group Limited Anhydrous crystal form of valaciclovir hydrochloride
CA2465928C (en) * 2001-11-14 2010-01-19 Teva Pharmaceutical Industries Ltd. Synthesis and purification of valacyclovir
EP1517678A2 (en) * 2002-06-24 2005-03-30 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
WO2004035583A1 (en) * 2002-10-16 2004-04-29 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
CA2548608A1 (en) * 2002-12-09 2004-06-24 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
WO2004106338A1 (en) * 2003-05-30 2004-12-09 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Novel crystalline forms of valacyclovir hydrochloride
EP2014660A3 (en) 2003-06-02 2009-07-15 Teva Pharmaceutical Industries Ltd Novel crystalline forms of valacyclovir hydrochloride
WO2005073233A1 (en) * 2004-01-21 2005-08-11 Teva Pharmaceutical Industries Ltd. Process for the preparation of valacyclovir hydrochloride
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
CA2572268A1 (en) * 2004-06-30 2006-02-02 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US20060178512A1 (en) * 2005-02-04 2006-08-10 Cheruthur Govindan Method for preparing amino acid esters of nucleoside analogues
ATE546451T1 (de) * 2005-05-25 2012-03-15 Lilly Co Eli Cyclopropancarbonsäureester von acyclovir
EP1746098A1 (en) 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process
NZ600394A (en) * 2006-05-04 2014-04-30 Boehringer Ingelheim Int Polymorphs of a dpp-iv enzyme inhibitor
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
CN1903854B (zh) * 2006-08-09 2012-05-23 丽珠医药集团股份有限公司 一种合成盐酸伐昔洛韦的方法
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20080281099A1 (en) * 2007-05-07 2008-11-13 Mayur Devjibhai Khunt Process for purifying valacyclovir hydrochloride and intermediates thereof
GB0710277D0 (en) * 2007-05-30 2007-07-11 Univ Birmingham Use of antivirals in the treatment of medical disorders
NZ600126A (en) * 2007-08-17 2013-12-20 Boehringer Ingelheim Int Purine derivatives for use in the treatment of fap-related diseases
JPWO2009031576A1 (ja) * 2007-09-03 2010-12-16 味の素株式会社 バラシクロビル塩酸塩結晶の製造方法
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0917675A2 (pt) * 2008-08-15 2015-12-01 Boehringer Ingelheim Int compostos orgânicos para cura de ferida
WO2010029089A2 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR20110103968A (ko) 2008-12-23 2011-09-21 베링거 인겔하임 인터내셔날 게엠베하 유기 화합물의 염 형태
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
KR20190071840A (ko) 2009-11-27 2019-06-24 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
PH12012502162A1 (en) 2010-05-05 2013-02-04 Boehringer Ingelheim Int Combination therapy
WO2011158252A1 (en) 2010-06-15 2011-12-22 Matrix Laboratories Ltd Process for the preparation of valacyclovir hydrochloride polymorphic form ii
EP2585101A1 (en) 2010-06-24 2013-05-01 Boehringer Ingelheim International GmbH Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CN102584825B (zh) * 2011-01-17 2014-04-02 四川科伦药物研究有限公司 一种合成盐酸伐昔洛韦的方法
EP3517539B1 (en) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
EP2852592A4 (en) * 2011-11-25 2015-12-23 Piramal Entpr Ltd PROCESS FOR THE PREPARATION OF VALACYCLOVIR CHLORHYDRATE
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849754B1 (en) 2012-05-14 2022-09-14 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
KR102391564B1 (ko) 2016-06-10 2022-04-29 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴 및 메트포르민의 병용물
CN110437231B (zh) * 2019-09-04 2022-04-29 上药康丽（常州）药业有限公司 一种盐酸伐昔洛韦无水晶型ⅰ的制备方法
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP55A (en) * 1987-08-15 1989-09-26 The Wellcome Foundation Ltd Therapeutic Acyclic Nucleosides
ES2157259T3 (es) * 1993-06-10 2001-08-16 Rolabo Sl Procedimiento para preparar esteres de aminoacidos y analogos de nucleosidos.
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative

Also Published As

Publication number Publication date
EP0804436A1 (en) 1997-11-05
NO973326L (no) 1997-09-16
ZA96449B (en) 1996-08-07
JP3176633B2 (ja) 2001-06-18
ATE302777T1 (de) 2005-09-15
EE9700175A (et) 1998-02-16
HUP9801836A3 (en) 1999-06-28
GB9501178D0 (en) 1995-03-08
KR100376074B1 (ko) 2003-06-02
NO315558B1 (no) 2003-09-22
BG63393B1 (bg) 2001-12-29
CN1049893C (zh) 2000-03-01
IS2268B (is) 2007-07-15
KR19980701525A (ko) 1998-05-15
AP9701058A0 (en) 1997-10-31
EA000364B1 (ru) 1999-06-24
BR9606768A (pt) 1997-12-30
PL182175B1 (pl) 2001-11-30
US6107302A (en) 2000-08-22
AU4453996A (en) 1996-08-07
FI973063L (fi) 1997-09-18
AP662A (en) 1998-08-19
MX9705462A (es) 1997-10-31
CZ297065B6 (cs) 2006-08-16
CA2210799C (en) 2008-06-10
NO973326D0 (no) 1997-07-18
DE69635106T2 (de) 2006-06-08
SK96597A3 (en) 1998-02-04
ES2248806T3 (es) 2006-03-16
NZ298851A (en) 1999-01-28
RO118693B1 (ro) 2003-09-30
UA46001C2 (uk) 2002-05-15
HUP9801836A2 (hu) 1999-05-28
PL321326A1 (en) 1997-12-08
DE69635106D1 (de) 2005-09-29
CY2531B1 (en) 2006-04-12
UY25779A1 (es) 2000-08-21
EP0804436B1 (en) 2005-08-24
IL116831A0 (en) 1996-05-14
RS49518B (sr) 2006-10-27
JPH11503718A (ja) 1999-03-30
HRP960024A2 (en) 1997-10-31
GEP20001940B (en) 2000-02-05
WO1996022291A1 (en) 1996-07-25
IN182468B (index.php) 1999-04-17
FI973063A0 (fi) 1997-07-18
FI973063A7 (fi) 1997-09-18
IL116831A (en) 1998-10-30
IS4527A (is) 1997-07-15
EA199700124A1 (ru) 1997-12-30
YU3396A (sh) 1998-12-23
HRP960024B1 (en) 2005-08-31
EE03528B1 (et) 2001-10-15
AU702794B2 (en) 1999-03-04
HU222993B1 (hu) 2004-01-28
CN1179159A (zh) 1998-04-15
TR199700656T1 (xx) 1998-03-21
DK0804436T3 (da) 2005-12-27
CA2210799A1 (en) 1996-07-25
SK285329B6 (sk) 2006-11-03
BG101833A (bg) 1998-04-30
CZ229497A3 (en) 1997-12-17
AR002270A1 (es) 1998-03-11
SI0804436T1 (sl) 2006-02-28

Similar Documents

Publication Publication Date Title
OA10499A (en) Guanine derivative
OA10500A (en) Valaciclovir tablets containing colloidal silicon dioxide
EP1071693B1 (en) Novel crystalline forms of an antiviral benzimidazole compound
CA2327495C (en) Form vi 5,6-dichloro-2-(isopropylamino)-1-(.beta.-l-ribofuranosyl)-1h-benzimidazole
HK1003055B (en) Guanine derivative
HK1003055A1 (en) Guanine derivative
MXPA97005462A (en) Derived from guan
CN115385931A (zh) 多替拉韦钠的多晶型物及其制备方法
WO2007039919A1 (en) Crystalline forms of anastrozole
HK1032060B (en) Form vi 5,6-dichloro-2-(isopropylamino)-1-beta-l-ribofuranosyl)-1h-benzimidazole
MXPA00009734A (en) Novel crystalline forms of an antiviral benzimidazole compound